RxDoctor Payments Data

Michael Uzer, MD

Gastroenterology · Burlington, VTNPI 1295733475

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 49.2% of the total. Reporting peaked in 2023 at $456 and has fallen 62.2% since, to $173 in 2025.

$1,707in general payments, 2019–2025

Across 91 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$840
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$208
  • Takeda Pharmaceuticals U.S.A., Inc.$162
  • Johnson & Johnson$124
  • Gilead$115
  • UCB, Inc.$64
  • plus $194 from 7 others

What the payments were for

  • Food & beverage$1,707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,707 in reported general payments places this provider in the 75th percentile of 25 gastroenterology providers in Vermont.

See all gastroenterology providers in Vermont

Medicare billing

Part B allowed, 2024
$47,243
Medicare patients
208
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg102$1,902
Sulfasalazine DrSulfasalazine11$337
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl19$293
Pantoprazole Sodium43$292
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg20$241
Omeprazole26$237
Imipramine Hcl12$188

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →